+
Site Tour
AMPLATZER™ TALISMAN™
PFO OCCLUDER
STRUCTURAL INTERVENTIONS

 

Effective patent foramen ovale (PFO) closure is made easier with the Amplatzer™ Talisman™ PFO Occluder.1 For patients who have experienced a PFO-associated stroke, clinical trials have shown that they can benefit from PFO closure.2–4 This minimally invasive procedure significantly

SWITCH TO THE REFERRAL VIEW    For more information specific to neurology regarding PFO closure 

THE PIONEER IN PFO CLOSURE1

As the device that created the category, the Amplatzer™ Talisman™ PFO Occluder has sustained leadership over decades of use by pursuing clinical evidence to become the first device supported by positive PFO trial results.2

Today, it is the most studied device of its kind, with over 180,000 patients treated worldwide.1 And our clinical evidence is unmatched, thanks to the largest ever trial for PFO closure, boasting 5,810 patient-years of data.2

ABOUT THE AMPLATZER™ TALISMAN™ PFO OCCLUDER

With the Amplatzer™ Talisman™ PFO Occluder, the device you know and trust just got better. It is built on the proven Amplatzer™ PFO closure technology and the Amplatzer™ Trevisio™ Delivery System, with key enhancements to make it our most advanced and easy-to-use PFO closure device yet:

  • The occluder comes assembled and ready to use, simplifying preparation and enhancing ease of use
  • We re-engineered the 30 mm size with a smaller left atrial disc to better avoid interference with surrounding structures

THE PFO OCCLUDER TRUSTED BY THOUSANDS OF PHYSICIANS AROUND THE WORLD1

WE SET THE STANDARD

  • Pioneered treatment with a PFO-specific device
  • Available in over 80 countries around the world

WE RAISE THE BAR

  • With the landmark RESPECT trial,2 we had the most extensive patient follow-up, almost 2x more than other PFO trials
  • RESPECT was also the only trial to include patients on anticoagulation therapy, a real-world cross-section of patients

WE DEMONSTRATE EXCELLENCE

  • ZERO device erosions, thrombus, or embolization events in 6 published trials with 990 patients
  • 94.2% effective closure rate at 6 months

HOW TO IMPLANT THE AMPLATZER™
TALISMAN™ PFO OCCLUDER

Watch the Amplatzer™ Talisman™ PFO Occluder implant procedure video.

Connext
TV

CONNECT TO THE LATEST
IN STRUCTURAL HEART
THERAPY

Find out more

TV

References
  1. Data on file at Abbott.
  2. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022–1032. doi.org/10.1056/NEJMoa1610057.
  3. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033–1042. doi.org/10.1056/NEJMoa1707404.
  4. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011–1021 and supplementary appendix. doi.org/10.1056/NEJMoa1705915.
  5. Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020;94(20):876–885. doi.org/10.1212/WNL.0000000000009443.

© Abbott 2023. All rights reserved. 9-EH-5-14385-01 07-2023

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline